Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study.
A novel two-target cancer drug shows promise in patients whose tumors resisted prior treatments, potentially opening new avenues when single-target approaches fail.
This Phase 1b study of iza-bren—a novel bispecific ADC simultaneously targeting EGFR and HER3—reports promising antitumor activity and acceptable safety in patients with advanced solid tumors who progressed on prior standard therapies. The first-in-class bispecific ADC design addresses a key resistance mechanism to monospecific ADCs and EGFR-targeted therapies, opening a new therapeutic approach.
What the study was
- Study design
- Phase 1b clinical trial
- Population
- Advanced solid tumor patients (EGFR-mutated and wild-type)
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Annals of oncology : official journal of the European Society for Medical Oncology
Why it surfaced
First-in-class EGFR-HER3 bispecific ADC with Phase 1b clinical evidence of activity in heavily pretreated solid tumors; represents a potentially transformative new treatment class.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.